Last updated: February 7, 2026
Overview
PALLADONE, the brand name for hydromorphone hydrochloride extended-release capsules, was developed to provide long-acting relief for moderate to severe pain. Manufactured originally by Purdue Pharma, the drug class falls under opioids with high potency and risk of dependence. Marketed primarily in the United States and some international regions, PALLADONE has experienced market withdrawal due to safety concerns but remains relevant in the landscape of opioid analgesics.
Clinical Trials Status
PALLADONE has undergone multiple clinical trials focusing on efficacy and safety for pain management.
-
Initial Trials (Pre-approval): Conducted prior to 1980s FDA approval, these focused on pharmacokinetics, efficacy, and side-effect profiles. Results demonstrated superior pain relief compared to weaker opioids with significant CNS side effects at higher doses.
-
Post-market Studies: Between the late 1990s and early 2000s, clinical investigations explored long-term safety, dependence potential, and overdose risk. These studies highlighted risks of respiratory depression and abuse potential typical of opioids.
-
Revocation and Discontinuation: PALLADONE was voluntarily withdrawn from the U.S. market in 2005 following reports of overdose deaths related to misuse and abuse, despite ongoing trials exploring safer formulations.
-
Current Trials: No active clinical trials for PALLADONE are registered with clinicaltrials.gov as of 2023. The product's market withdrawal limits further investigations or post-marketing studies under its name.
Implication for Development: The regulatory and safety profile issues have effectively halted new clinical trials, limiting potential relaunch or reformulation efforts.
Market Landscape
The market for opioid analgesics is characterized by high demand for effective pain management and escalating concerns over misuse and regulatory restrictions.
| Segment |
Data |
Context |
| Market size (2022) |
Estimated $8 billion globally |
Driven by chronic pain, post-surgical pain, cancer pain. |
| Major players |
Purdue Pharma (withdrawn PALLADONE), Purdue's alternative formulations, ER formulations from Teva, Mylan, and others |
PALLADONE's withdrawal created opportunities for competitors. |
| Market share (2022) |
Hydromorphone (including PALLADONE) held approx. 10-15% of opioid analgesic prescriptions in the US |
Dominated by immediate-release formulations due to safety concerns over ER formulations. |
Regulatory Environment
- The US FDA issued warnings and ultimately facilitated the voluntary withdrawal of PALLADONE in 2005.
- Many regions are enforcing stricter control measures, including scheduling controls (PALLADONE was Schedule II under the Controlled Substances Act).
- Reformulation to reduce abuse potential, such as abuse-deterrent formulations, has gained traction, but PALLADONE itself remains unavailable.
Market Projection
The global opioid analgesics market is projected to grow at a CAGR of approximately 3.8% from 2023 to 2030. While PALLADONE's market share has diminished, opportunities exist for newer, abuse-deterrent formulations of hydromorphone or similar opioids.
-
Opportunities in Reformulation: Development of next-generation formulations with abuse-deterrent properties could reintroduce hydromorphone as a safer option.
-
Impact of Regulatory Wind: Stricter controls are expected to limit growth but could favor formulations with lower abuse potential.
-
Perception and Litigation Risks: Ongoing lawsuits related to opioid dependency and abuse could influence future development and approval trajectories.
Key Takeaways
- PALLADONE's original formulation has been discontinued due to safety and abuse concerns.
- Clinical trials have not been active since the early 2000s, reflecting regulatory actions.
- The opioid analgesics market remains significant but heavily regulated.
- Growth depends on reformulation efforts that address safety, with abuse-deterrent technologies leading the focus.
- Future opportunities hinge on regulatory approval processes, safety profiles, and market acceptance.
FAQs
1. Is PALLADONE available in any markets today?
No. PALLADONE was withdrawn from the U.S. market in 2005 and is not available in major pharmaceutical markets due to safety concerns.
2. Are there any ongoing clinical trials for similar opioids?
Yes. Several companies are developing abuse-deterrent formulations of hydromorphone and other opioids, with some in late-stage clinical trials focusing on safety and efficacy.
3. Could PALLADONE or its formulations be reintroduced?
Reintroduction would require significant reformulation to mitigate abuse and safety risks, plus regulatory approval based on new clinical data.
4. How does the market for opioids evolve with increasing restrictions?
Market growth slows; focus shifts toward non-opioid analgesics and abuse-deterrent formulations. Prescriptions for ER opioids decline in favor of safer options.
5. What legal and regulatory factors influence opioid drug development?
Stringent scheduling laws, FDA safety requirements, and increasing litigation create barriers. Reformulation with abuse-deterrent features is increasingly necessary for new approvals.
Sources
[1] U.S. Food and Drug Administration. (2005). "FDA Warns about Risks of Abuse and Overdose with PALLADONE."
[2] MarketWatch. (2022). "Global Opioid Analgesics Market Size & Growth."
[3] ClinicalTrials.gov. (2023). "Status of PALLADONE Trials and Related Opioid Studies."
[4] IQVIA Institute. (2023). "Opioid Use and Market Trends."
